198 related articles for article (PubMed ID: 26694323)
1. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada.
Teela KC; De Silva DA; Chapman K; Synnes AR; Sawchuck D; Basso M; Liston RM; von Dadelszen P; Magee LA;
BMC Pregnancy Childbirth; 2015 Dec; 15():347. PubMed ID: 26694323
[TBL] [Abstract][Full Text] [Related]
2. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada.
De Silva DA; Synnes AR; von Dadelszen P; Lee T; Bone JN; ; Magee LA
Implement Sci; 2018 Jan; 13(1):8. PubMed ID: 29325592
[TBL] [Abstract][Full Text] [Related]
3. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection.
Magee L; Sawchuck D; Synnes A; von Dadelszen P; ;
J Obstet Gynaecol Can; 2011 May; 33(5):516-529. PubMed ID: 21639972
[TBL] [Abstract][Full Text] [Related]
4. No. 376-Magnesium Sulphate for Fetal Neuroprotection.
Magee LA; De Silva DA; Sawchuck D; Synnes A; von Dadelszen P
J Obstet Gynaecol Can; 2019 Apr; 41(4):505-522. PubMed ID: 30879485
[TBL] [Abstract][Full Text] [Related]
5. Working to improve survival and health for babies born very preterm: the WISH project protocol.
Crowther CA; Middleton PF; Bain E; Ashwood P; Bubner T; Flenady V; Morris J; McIntyre S;
BMC Pregnancy Childbirth; 2013 Dec; 13():239. PubMed ID: 24354790
[TBL] [Abstract][Full Text] [Related]
6. Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework.
Bain E; Bubner T; Ashwood P; Van Ryswyk E; Simmonds L; Reid S; Middleton P; Crowther CA
BMC Pregnancy Childbirth; 2015 Aug; 15():176. PubMed ID: 26283623
[TBL] [Abstract][Full Text] [Related]
7. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis.
Wolf HT; Huusom LD; Henriksen TB; Hegaard HK; Brok J; Pinborg A
BJOG; 2020 Sep; 127(10):1180-1188. PubMed ID: 32237069
[TBL] [Abstract][Full Text] [Related]
8. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.
Crowther CA; Middleton PF; Voysey M; Askie L; Duley L; Pryde PG; Marret S; Doyle LW;
PLoS Med; 2017 Oct; 14(10):e1002398. PubMed ID: 28976987
[TBL] [Abstract][Full Text] [Related]
9. Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand - Ongoing barriers and enablers.
Gatman K; May R; Crowther C
Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):44-48. PubMed ID: 31119725
[TBL] [Abstract][Full Text] [Related]
10. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews.
Shepherd E; Salam RA; Middleton P; Makrides M; McIntyre S; Badawi N; Crowther CA
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012077. PubMed ID: 28786098
[TBL] [Abstract][Full Text] [Related]
11. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection.
Obstet Gynecol; 2010 Mar; 115(3):669-671. PubMed ID: 20177305
[TBL] [Abstract][Full Text] [Related]
12. Nonreceipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-2013.
Siwicki K; Bain E; Bubner T; Ashwood P; Middleton P; Crowther CA
Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):233-8. PubMed ID: 26084194
[TBL] [Abstract][Full Text] [Related]
13. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres.
De Silva DA; Sawchuck D; von Dadelszen P; Basso M; Synnes AR; Liston RM; Magee LA
J Obstet Gynaecol Can; 2015 Nov; 37(11):975-87. PubMed ID: 26629718
[TBL] [Abstract][Full Text] [Related]
14. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial.
Wolf HT; Brok J; Henriksen TB; Greisen G; Salvig JD; Pryds O; Hedegaard M; Weber T; Hegaard HK; Pinborg A; Huusom LD;
BJOG; 2020 Sep; 127(10):1217-1225. PubMed ID: 32237024
[TBL] [Abstract][Full Text] [Related]
15. [Neuroprotection for preterm infants with antenatal magnesium sulphate].
Marret S; Ancel PY
J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1418-1433. PubMed ID: 28166926
[TBL] [Abstract][Full Text] [Related]
16. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
Doyle LW; Crowther CA; Middleton P; Marret S
Cochrane Database Syst Rev; 2007 Jul; (3):CD004661. PubMed ID: 17636771
[TBL] [Abstract][Full Text] [Related]
17. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.
Crowther CA; Middleton PF; Wilkinson D; Ashwood P; Haslam R;
BMC Pregnancy Childbirth; 2013 Apr; 13():91. PubMed ID: 23570677
[TBL] [Abstract][Full Text] [Related]
18. [Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth].
Wolf HT; Henriksen TB; Larsen ML; Pinborg A; Hegaard HK; Brok JS; Huusom LD
Ugeskr Laeger; 2020 Nov; 182(47):. PubMed ID: 33215580
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit.
Ow LL; Kennedy A; McCarthy EA; Walker SP
Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):356-60. PubMed ID: 22515404
[TBL] [Abstract][Full Text] [Related]
20. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.
Bickford CD; Magee LA; Mitton C; Kruse M; Synnes AR; Sawchuck D; Basso M; Senikas VM; von Dadelszen P;
BMC Health Serv Res; 2013 Dec; 13():527. PubMed ID: 24350635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
